Joint comfort

Pain↓ Function↑

Pain↓ Function↑

Pain/function ↓

Cartilage loss ↓

Pain/function relief −76%

Joint-space loss −0.25 mm

Pain/function improved

Cartilage breakdown markers ↓

Less pain, stiffness

Lower inflammation markers

Joint pain/stiffness ↓

DAS28/NSAID ↓

Pain ↓, function ↑

CTX-II ↓ or ↑

Pain/function ↓

Inflammation markers ↓

Pain ↓, function ↑

+29.2–41.8 m

Inflammation ↓

Pain/function improve

Inflammation biomarkers drop

Pain/function better

Inflammation down

Pain/function +20-80%

Deposit resorption

Joint-space/BMD +2%

Pain/function relief

Collagen synthesis +30g

Joint comfort +RA

Pain/stiffness −5 to −10

Pain & function: +relief

Swelling/stiffness: -20% relapse

Pain/function: -3.2

Inflammation/stiffness: improved

Pain/function ↓; NSAID −26%

Joint space progression ↓ ~10%

Pain/function −2.8

NSAID use ↓

Pain/function +6.8s

Pain/tenderness ↓, +41%

Stiffness/function improved, ~−3

Collagen synthesis +100%

OA pain/function ~50%

Pain relief, better tolerance

Cartilage scores, lower lesions

Pain/function improved

Activity/lameness improved

Pain reduced

Joint function improved

Pain ↓, disability ↓

QoL ↑, success ↑

Pain/function improvements

CRP/EPA changes

Pain relief similar vs NSAIDs

Tenderness down; liver enzymes +

Pain/function improved

Uric acid -26.5

Vitamin D +11.9

Anti-inflammatory fatty acids

Joint pain/stiffness ↓

AA:EPA -1.9 pp

Hand OA −44%

RA inflammation ↓

Leg cramps −2.67/week

Pain/function +24%

+23% fewer side effects

Pain/function improved

-34% pain, -28% function

Massage/reflexology eased pain

Pain ↓

Function ↑

Improved joint repair

Pain/function better

Pain/function improved

WOMAC pain -1.41

RA function improved

Joint pain unchanged; men improved

Stiffness/pain improved, biomarkers down

Joint pain ~50% less

Pain relief, +13 mm

Better function/walking

Pain/function ↓ −12.2

Pain/joints/inflammation ↓

Pain/function, −20.8 mm

Inflammation, CRP↓

Pain -27%

Exam/severity -43%

BCTQ symptoms/function −10.3

NCV +2.38 m/s

Pain/inflammation ↓

Tender joints −1.38

Treg/miRNA shifts

Pain ↓, disability ↓

Joint pain relief

Pain/function: no change

Pain/opening: improves

Pain/ROM/daily activity

Mouth opening +11–18 mm

Pain eased similarly

Function improved; fewer AEs

Month 1: +9.3, +11.6

Knee: LFI −3.6

Hip: WOMAC improved

Pain/function improved

Analgesic use -10

Pain relief -14%

Stiffness/function NR

Pain ↓; stiffness ↓

Threshold ↑; pain ↓

Pain/function improved

PGE2 down

Pain/disability; +9 responders

Mobility; greater pain drop

Pain −35%

Inflammation lower

DAS28 −1.0, pain

Morning stiffness only

PGE2, pain improved

IL-4, IL-6, hs-CRP down

Less pain/stiffness

Lower inflammation, better comfort

Pain -53% joints

Assessment scores improved

Pain ↓; inflammation ↓

Tender/swollen joints ↓

Trismus +4.8–7.5 mm

Swelling -2 to -4.7 mm

Pain unchanged

Pain −50–63%

Inflammation −24–47%

Muscle/joint pain -10

Hot flashes, dose-related

Bone turnover -15%

Pain scores improved

Pain -1.19

Function -0.89

NSAID use down +29%

Joint comfort unchanged

Pain/stiffness/motion improved

No between-group difference

Pain/function better

QoL improved

Less pain, stiffness

Lower disease activity

Pain/stiffness ↓

ROM ↑

Less arthritis impact, +29%

Better mobility, +4.5°

Pain relief -1.78

Inflammation unchanged

Strength loss ↓6.6pp

Collagen marker ↓38%

Pain/function + p<0.001

Menopausal symptoms + p<0.001

Lower PGE2

Similar to naproxen

Pain/disability relief

QoL gain

Better joint symptoms; ASAS20 +26.9%

Lower inflammation (CRP)

Inflammation down; pain relief

-

Joint markers down

Joint pain/function ↓

Pain ↓66%

Synovial ITCs +497 nM

Plasma ITCs +0.86 μM

Joint proteins altered

Inflammation down, comfort likely better

TAC up, joint support